Author:
Sethi Sunil,Golparian Daniel,Bala Manju,Dorji Dorji,Ibrahim Muhammad,Jabeen Kausar,Unemo Magnus
Abstract
Abstract
Background
Knowledge on antimicrobial drug resistance and genetic characteristics of Neisseria gonorrhoeae isolates circulating in India, Pakistan, and Bhutan is sorely lacking. In this paper, we describe the prevalence of antimicrobial resistance and molecular characteristics of N. gonorrhoeae isolates from India, Pakistan, and Bhutan in 2007–2011.
Methods
Antimicrobial susceptibility and β-lactamase production were tested for 65 N. gonorrhoeae isolates from India (n=40), Pakistan (n=18) and Bhutan (n=7) using Etest methodology (eight antimicrobials) and nitrocefin solution, respectively. Resistance determinants, i.e. penA, mtrR, porB1b, gyrA, and parC, were sequenced. N. gonorrhoeae multiantigen sequence typing (NG-MAST) was performed for molecular epidemiology.
Results
The highest resistance level was observed for ciprofloxacin (94%), followed by penicillin G (68%), erythromycin (62%), tetracycline (55%), and azithromycin (7.7%). All the isolates were susceptible to ceftriaxone, cefixime, and spectinomycin. Thirty-four (52%) of the isolates were producing β-lactamase. No penA mosaic alleles or A501-altered alleles of penicillin-binding protein 2 were identified. Forty-nine NG-MAST STs were identified, of which 42 STs have not been previously described worldwide.
Conclusions
Based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line therapy for gonorrhoea in India, Pakistan, and Bhutan, whereas ciprofloxacin, penicillin G, tetracycline, erythromycin, and azithromycin should not be. It is imperative to strengthen the laboratory infrastructure in this region, as well as to expand the phenotypic and genetic surveillance of antimicrobial resistance, emergence of new resistance, particularly, to extended-spectrum cephalosporins, and molecular epidemiology.
Publisher
Springer Science and Business Media LLC
Reference63 articles.
1. World Health Organization (WHO): Global incidence and prevalence of selected curable sexually transmitted infections - 2008. 2012, Geneva: World Health Organization, Available at: http://www.who.int/reproductivehealth/publications/rtis/2008_STI_estimates.pdf (Accessed: December 20, 2012)
2. World Health Organization (WHO): Prevalence and incidence of selected sexually transmitted infections: Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis. Methods used by WHO to generate 2005 estimates. 2011, Geneva: World Health Organization, ISBN:978 92 4 150245 0
3. Tapsall J: Antimicrobial resistance in Neisseria gonorrhoeae. WHO/CDS/DRS/2001.3:16. 2001, Geneva: World Health Organization
4. Tapsall JW, Ndowa F, Lewis DA, et al: Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Exp Rev Anti Infect Ther. 2009, 7: 821-834. 10.1586/eri.09.63.
5. World Health Organization (WHO) Department of Reproductive Health and Research: Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. 2012, Geneva: WHO, 1-36. Available at: http://www.who.int/reproductivehealth/publications/rtis/9789241503501 (Accessed: December 20, 2012)